Sign In
3 Mar 2015 07:00
3 March 2015
Tiziana Life Sciences plc
Grant of Options
London, 3 March 2015 - Tiziana Life Sciences plc ("Tiziana" or the "Company", AIM: TILS), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, announces that it has granted 600,000 options to subscribe for ordinary shares in the Company to an experienced clinical consultant to the Company ("Options").
The Options are exercisable at a price of 55 pence per share and shall vest in four equal instalments on the first, second, third and fourth anniversaries of the date of grant. The Options expire on the tenth anniversary of the date of grant, being 2 March 2025.
Contacts:
Tiziana Life Sciences plc Philip Boyd, CFO | +44 (0)20 7493 2853 |
Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Avi Robinson |
+44 (0)20 7148 7900 |
Beaufort Securities Limited (Broker) Saif Janjua |
+44 (0)20 7382 8300 |
FTI Consulting Simon Conway / Rob Winder / Natalie Garland-Collins |
+44 (0)20 3727 1000 |
TILS.L (TILS)
Follow the stocks
